Abstract 1572P
Background
The determinants of choices of orientation towards medical oncology have been little explored.
Methods
Medical students of the classes 2022 and 2023 in Lille and Amiens Universities (North of France) were enrolled in a quantitative online survey, with 2 follow-up over 2 months. 36 potential determinants from previous works (Wright et al. 2004; Beaulieu et al. 2010) were evaluated using a 5-point Likert scale alongside parameters. Choosing oncology was assessed among 44 specialities. We identified determinants using both CHAID method and binary and multiple linear regressions, and CHAID method.
Results
Responders were 563 (563/1250; 45%). CHAID analysis retained 2 factors: “medical oncology traineeship” (p<.0001) and “identification with a doctor in the specialty” (p=.049). when excluding factors associated with énd-cycle trining, CHAID analysis retained 2 factors associated with a career choice in oncology: “rejection of emergency care” (p=.036) and “wish of hospital-university career” (p=.006). Motivations differed according to sexes. In men, choosing oncology was associated in multivariate analysis with: “hospital traineeship in medical oncology” (β=0.22; p=.010), “hospital traineeship in oncology radiotherapy” (β=0.22; p<0.001) and “interest in fundamental research” (β=0.06; p<.001). Conversely, “rural life” (β=-0.09; p=.014) was negatively associated with this choice. In women, parameters positively associated with choosing oncology were: “hospital traineeship in medical oncology” (β=0.289; p<.001), “long-term relationship with patients” (β=0.12; p=.021) and “hospital work” (β=0.21; p=0<.001). A negative association was observed for: “treatment with visible outcome in the short term” (β=-0.15; p=.018) and “rural life” (β=-0.15; p=.006).
Conclusions
Motivations varied according to sexes. Hospital experience during the second cycle of medical studies plays a determining role. The ability or the interest in emergency management seems important in career choice. Certain interests influence career choice (long-term relationship with patient) as well as contextual factors (rural life). These results can be interpreted according to Bandura's social cognitive theory.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Oscar Lambret.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10